Realising milestones with gene therapy for SMA
Novartis Gene Therapies' Dr Sitra Tauscher-Wisniewski shares what shaped the success of one of the few commercially-available gene therapies.
Source: europeanpharmaceuticalreview.com
Clinical Development Analytics News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Clinical Development Analytics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Clinical Development Analytics Today - Breaking & Trending Today
Novartis shares Zolgensma long-term data demonstrating
Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll...
Source: globenewswire.com
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
20.03.2023 - Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all ...
Source: wallstreet-online.de
Novartis Pharma AG: Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous cohort
Source: finanznachrichten.de
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
BASEL (dpa-AFX) - Novartis AG (NVS) Monday presented new long-term data of Zolgensma (onasemnogene abeparvovec), the only approved one-time gene therapy for the treatment of spinal muscular atrophy
Source: finanznachrichten.de